Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators

JACC: Clinical Electrophysiology

Volumn 3, Issue 1, 2017, Pages 50-56

  Enriquez, Andrés ^a   Biagi, Jim ^b   Redfearn, Damian ^a   Boles, Usama ^a   Kamel, Dalia ^b   Ali, Fariha Sadiq ^a   Hopman, Wilma M ^a   Michael, Kevin A ^a   Simpson, Christopher ^a   Abdollah, Hoshiar ^a   Campbell, Debra ^a   Baranchuk, Adrian ^a  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b Cancer Center of Southeastern Ontario   (Canada)

Author keywords

cancer; cardiotoxicity; ICD; ventricular tachycardia

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; ATRIAL FIBRILLATION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; ADVERSE DEVICE EFFECT; COMPLICATION; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY;

AGED; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; RETROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 85008155386     PISSN: 2405500X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacep.2016.03.001     Document Type: Article

References (30)

1. 1 Go, A.S., Mozaffarian, D., Roger, V.L., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), 399–410.
2. 2 Tomaselli, G.F., Zipes, D.P., What causes sudden death in heart failure?. Circ Res 95 (2004), 754–763.
3. 3 Yeh, E.T., Bickford, C.L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 (2009), 2231–2247.
4. 4 Barbey, J.T., Pezzullo, J.C., Soignet, S.L., Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21 (2003), 3609–3615.
5. 5 Kantarjian, H.M., Giles, F., Gattermann, N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007), 3540–3546.
6. 6 Butany, J., Nair, V., Naseemuddin, A., Nair, G.M., Catton, C., Yau, T., Cardiac tumours: diagnosis and management. Lancet Oncol 6 (2005), 219–228.
7. 7 Reynen, K., Köckeritz, U., Strasser, R.H., Metastases to the heart. Ann Oncol 15 (2004), 375–381.
8. 8 Kowey, P.R., Levine, J.H., Herre, J.M., et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 92 (1995), 3255–3263.
9. 9 Verma, A., Kilicaslan, F., Marrouche, N.F., et al. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol 15 (2004), 1265–1270.
10. 10 Israel, C.W., Barold, S.S., Electrical storm in patients with an implanted defibrillator: a matter of definition. Ann Noninvasive Electrocardiol 12 (2007), 375–382.
11. 11 Kremers, M.S., Hammill, S.C., Berul, C.I., et al. The National ICD Registry report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm 10 (2013), e59–e65.
12. 12 Pedersen, S.B., Nielsen, J.C., Bøtker, H.E., Farkas, D.K., Schmidt, M., Sørensen, H.T., Implantable cardioverter-defibrillators and subsequent cancer risk: a nationwide population-based cohort study. Europace 17 (2015), 902–908.
13. 13 Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
14. 14 Kundu, J.K., Surh, Y.J., Inflammation: gearing the journey to cancer. Mutat Res 659 (2008), 15–30.
15. 15 Streitner, F., Kuschyk, J., Veltmann, C., et al. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine 47 (2009), 166–172.
16. 16 Albert, C.M., Ma, J., Rifai, N., Stampfer, M.J., Ridker, P.M., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105 (2002), 2595–2599.
17. 17 Elmas, E., Popp, T., Lang, S., Dempfle, C.E., Kälsch, T., Borggrefe, M., Sudden death: do cytokines and prothrombotic peptides contribute to the occurrence of ventricular fibrillation during acute myocardial infarction?. Int J Cardiol 145 (2010), 118–119.
18. 18 Mager, A., Strasberg, B., Zlotikamien, B., Kaplinsky, C., Sclarovsky, S., Life-threatening ventricular tachycardia as the presenting symptom of metastatic cardiac disease. Clin Cardiol 14 (1991), 696–698.
19. 19 Sheldon, R., Isaac, D., Metastatic melanoma to the heart presenting with ventricular tachycardia. Chest 99 (1991), 1296–1298.
20. 20 Sharma, J., Brunson, J.M., Memon, N., Khakoo, A.Y., Metastatic melanoma presenting as polymorphic ventricular tachycardia. Tex Heart Inst J 39 (2012), 890–893.
21. 21 Bussani, R., De-Giorgio, F., Abbate, A., Silvestri, F., Cardiac metastases. J Clin Pathol 60 (2007), 27–34.
22. 22 Steinberg, J.S., Arshad, A., Kowalski, M., et al. Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack. J Am Coll Cardiol 44 (2004), 1261–1264.
23. 23 Lampert, R., Jain, D., Burg, M.M., et al. Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Circulation 101 (2000), 158–164.
24. 24 Schron, E.B., Exner, D.V., Yao, Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105 (2002), 589–594.
25. 25 Lampert, R., Hayes, D.L., Annas, G.J., et al. American College of Cardiology American Geriatrics Society American Academy of Hospice and Palliative Medicine American Heart Association European Heart Rhythm Association, Hospice and Palliative Nurses Association. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 7 (2010), 1008–1026.
26. 26 Sherazi, S., McNitt, S., Aktas, M.K., et al. End-of-life care in patients with implantable cardioverter defibrillators: a MADIT-II substudy. Pacing Clin Electrophysiol 36 (2013), 1273–1279.
27. 27 Goldstein, N.E., Mehta, D., Siddiqui, S., et al. “That's like an act of suicide” patients' attitudes toward deactivation of implantable defibrillators. J Gen Intern Med 23:Suppl 1 (2008), 7–12.
28. 28 Tajouri, T.H., Ottenberg, A.L., Hayes, D.L., Mueller, P.S., The use of advance directives among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 35 (2012), 567–573.
29. 29 Kramer, D.B., Kesselheim, A.S., Brock, D.W., Maisel, W.H., Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm 7 (2010), 1537–1542.
30. 30 Goldstein, N., Bradley, E., Zeidman, J., Mehta, D., Morrison, R.S., Barriers to conversations about deactivation of implantable defibrillators in seriously ill patients: results of a nationwide survey comparing cardiology specialists to primary care physicians. J Am Coll Cardiol 54 (2009), 371–373.